← Leaderboards
Kathrin Meyer
Research Inst Nationwide Children'S Hosp
$2,136,536
Attributed
$3,134,927
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2015–23$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,134,927 · 2
By mechanism
R01$1,996,783 · 1
U01$1,138,144 · 1
Top collaborators
- Nicolas Wein5 shared
Most similar at Research Inst Nationwide Children'S Hosp
Same institution · by research overlap
- Brian K Kaspar$5,992,068
- Nicolas Wein$1,575,141
- Vidu Garg$10,712,827
- Catherine Dominguez$142,412
- Bruce A Bunnell$8,257,071
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsGenesNeonatalDoseNonhuman PrimateGeneticGene TherapyMouse ModelSafetyVirusBiodistributionOrganAntibodiesMotor NeuronsAdolescentBloodDisease ModelAdultAnterograde TransportDependovirusDisease PhenotypeCerebrospinal FluidAffectBurden Of Illness
Grant awards (6)
Alternative delivery of adeno-associated virus therapeutic vector for the treatment of neuromuscular disorders$321,752
R01 · FY2023 · AR
Alternative delivery of adeno-associated virus therapeutic vector for the treatment of neuromuscular disorders$345,017
R01 · FY2022 · AR
Alternative delivery of adeno-associated virus therapeutic vector for the treatment of neuromuscular disorders$382,447
R01 · FY2021 · AR
Alternative delivery of adeno-associated virus therapeutic vector for the treatment of neuromuscular disorders$487,911
R01 · FY2020 · AR
Alternative delivery of adeno-associated virus therapeutic vector for the treatment of neuromuscular disorders$459,656
R01 · FY2019 · AR
Translating a CSF delivered AAV9-SMN for treatment of Spinal Muscular Atrophy$1,138,144
U01 · FY2015 · NS · contact PI